VANCOUVER, BC / ACCESSWIRE / December 14, 2020 / NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSXV:NU)(OTCQB:NRXCF)(FRA:1N9), an innovative technology company developing products for the nutraceutical industry, in conjunction with partner, Tabletz LLC, is pleased to update details regarding the launch of the TABLETZ brand in Japan.
On behalf of the Tabletz brand, Masa Ikeda, Tabletz LLC., CEO, provided NeutriSci with the following progress update related to the Tabletz brand.
“I would like to thank NeutriSci and its Board members for the opportunity to provide an update to the shareholders of NeutriSci. I also thank both teams at NeutriSci and Tabletz for their efforts and dedication to this project. The tireless work has helped create an amazing brand, bringing us to the point where we are ready to introduce the product to the Japanese consumer.”
“To date, we have been able to establish the foundation for a sustained and long-term foothold in the Japanese marketplace, creating a buzz with our marketing and social media campaigns while building awareness in the community. Our packaging is unique, functional, and unmatched throughout the country. I can say, without hesitation, there is nothing like Tabletz anywhere in Japan, which gives us a distinct first mover advantage over any would be competition.”
Masa Ikeda went on to say “The last few months have been a challenge due to the COVID pandemic. Despite this, we have been able to push forward and create an amazing opportunity for our two companies. We have built the packaging, received approvals, procured orders, and readied the network of retail stores in grocery, drug and convenience, that will see the product launched across the country. All that is left is for us to receive is the customs import classification which is expected any day. This is an important final step in our process. We are the first company in Japan to bring this type of product to market. Our one-of-a-kind CBD tablet, with its unique formulation and delivery system, puts our product in a class of its own. Literally. The Japanese health ministry has put the application process for the importation of any new products on hold for the foreseeable future and halted the approval of new CBD products into the Japanese marketplace. This is a tremendous advantage for us as we maximize the first to market opportunity with a product that is different than the oils currently being sold. We anticipate the coming days and weeks ahead to be both exciting and rewarding for our two companies and their shareholders. I believe, based on our product offering, consumer, and retailer feedback as well as extensive pre orders’ we will be the best-selling brand in Japan.”
“Thank you again and Best Wishes to all for this Holiday Season!” Masa Ikeda, Tabletz LLC., CEO
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries. For more information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Tel: (403) 264-6320
For investor inquiries, please contact firstname.lastname@example.org
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.
SOURCE: NeutriSci International Inc
View source version on accesswire.com: